EVGN

Zoom conference call scheduled for November 19, 2026, 9:00 AM ET REHOVOT, Israel, Nov. 5, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the third quarter 2026, on Thursday , November 19, 2026.

The roadshow will connect leading Israeli AI-driven drug discovery and biotechnology companies with U.S. investors, pharmaceutical companies, and potential strategic partners REHOVOT, Israel, Oct. 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in AI-driven generative design of small molecules for pharmaceutical and agricultural applications, today announced its participation in the AI Drug Discovery Roadshow, taking place November 2-5, 2026, across the U.S. East Coast.

REHOVOT, Israel, Oct. 6, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it has entered into a comprehensive cooperation agreement (the "Agreement") with L.I.A.

REHOVOT, Israel, Sept. 30, 2026 /PRNewswire/ -- Evogene Ltd.

Company urges shareholders to evaluate the significant changes already implemented and vote FOR all Evogene nominees on September 4, 2026, Annual General Meeting REHOVOT, Israel, Aug. 31, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today responded to the latest communication from dissident shareholders L.I.A.

EverGen Infrastructure Corp. (EVGN:CA) Q2 2026 Earnings Call Transcript

VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN), is pleased to report the voting results from its Annual General Meeting of Shareholders (“AGM”) held on August 25, 2026. A total of 16,172,472 common shares were represented at the meeting, representing 62.43% of the Company's outstanding shares. The following is a summary of the proxy voting results for the AGM. 1. Election of Directors The following individuals were elected as.

EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript

Recommendations Reinforce Confidence in Evogene's Strategic Plan and Long-Term Value Creation Strategy  Board Urges Shareholders to Vote FOR All Evogene Nominees, and to disregard the Pure Capital Nominees, at the September 4, 2026, Annual General Meeting REHOVOT, Israel, Aug. 25, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced that leading independent proxy advisory firms Institutional Shareholder Services ("ISS") and Glass Lewis have recommended that Evogene shareholders vote "FOR" the Company slate of nominees in connection with the September 4, 2026 Annual General Meeting of Shareholders.

Company continues strategic transformation, initiated in 2025, into a focused, AI-driven computational chemistry company, with significant progress across pharmaceutical and agricultural product development programs Cash burn expected to decline to approximately $8.5–$9.5 million in 2026, compared with approximately $14.4 million in 2025 and approximately $20.5 million in 2024  Second-quarter net loss was reduced to approximately $1.8 million, compared with approximately $4.7 million in the second quarter of 2025 and approximately $6.0 million in the second quarter of 2024 Six active drug development collaborations established with biotechnology companies and leading academic institutions Virtual chemical space expanded to approximately 110 billion molecules, supported by advanced AI models and autonomous AI Agents REHOVOT, Israel, Aug. 18, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the first half of 2026 and second quarter ended June 30, 2026, and provided an update on its strategic and operational progress.